- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04105010
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)
This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment.
Phase 1 part:
Around 20~40 patients will be subsequently enrolled into 2 different dose ascending cohorts. Additional 10~20 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts.
Phase 2 part:
After the recommended phase 2 dose (RP2D) is defined, a phase 2 single-arm open-label pivotal study will be conducted to assess anti-tumor efficacy and safety of AZD4205 at RP2D in patients with refractory or relapsed PTCL.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Pamela Yang, MD, PhD
Study Contact Backup
- Name: Grace Yu, PhD
- Phone Number: 862161095854
- Email: grace.yu@dizalpharma.com
Study Locations
-
-
-
East Melbourne, Australia
- Epworth Hospital
-
Fitzroy, Australia
- St Vincent's Hospital Melbourne
-
Hobart, Australia
- Royal Hobart Hospital
-
Kogarah, Australia
- St George Hospital
-
Perth, Australia
- Royal Perth Hospital
-
Westmead, Australia
- Westmead Hospital
-
-
-
-
-
Beijing, China
- Peking University Third Hospital
-
Beijing, China
- Beijing Cancer Hospital
-
Beijing, China
- Beijing Friendship Hospital, Capital Medical University
-
Beijing, China
- Beijing Hospital
-
Changchun, China
- The First Hospital of Jilin University
-
Changsha, China
- Xiangya Hospital Central South University
-
Changsha, China
- Hunan Cancer Hospital
-
Chengdu, China
- Sichuan University - West China Hospital
-
Chongqing, China
- Chongqing University Cancer Hospital
-
Dalian, China
- The second hospital of Dalian medical university
-
Guangzhou, China
- Guangdong Provincial People's Hospital
-
Guangzhou, China
- Sun Yat-sen University Cancer Center
-
Guangzhou, China
- Nanfang Hospital of Southern Medical University
-
Haikou, China
- Hainan General Hospital
-
Hangzhou, China
- Zhejiang Cancer Hospital
-
Hangzhou, China
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Hefei, China
- The Second Hospital of Anhui Medical University
-
Hefei, China
- Anhui Provincial Cancer Hospital
-
Jinan, China
- Shandong Cancer Hospital
-
Lanzhou, China
- The First Hospital of Lanzhou University
-
Linyi, China
- Linyi Cancer Hospital
-
Nanchang, China
- The First Affiliated Hospital of Nanchang University
-
Nanchang, China
- Jiangxi Province Cancer Hospital
-
Nanjing, China
- Jiangsu Cancer Hospital
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
Shanghai, China
- Ruijin Hospital Shanghai Jiaotong University School of Medicine
-
Suzhou, China
- The First Affiliated Hospital of Soochow University
-
Tianjin, China
- Tianjin Medical University Cancer Institute and Hospital
-
Wuhan, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xiamen, China
- The First Affiliated hospital of Xiamen University
-
Zhengzhou, China
- Henan Cancer Hospital
-
-
-
-
-
Busan, Korea, Republic of
- Inje University Busan Paik Hospital
-
Busan, Korea, Republic of
- Pusan National University Hospital
-
Daegu, Korea, Republic of
- Keimyung University Dongsan Hospital
-
Goyang, Korea, Republic of
- National Cancer Center
-
Jeonju, Korea, Republic of
- Chonbuk National University Hospital
-
Seongnam, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of, 06133
- Samsung Medical Center
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Obtained written informed consent
- Patients must have histologically confirmed peripheral T-cell lymphoma according to the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Tumor samples are required for central pathology review to confirm the diagnosis.
- Patients must have measurable disease according to the Lugano criteria.
- Patients should be transplant-ineligible upon their entry into this study, and must have relapsed after or been refractory/intolerant to ≥ 1 (but not > 3) prior systemic therapy(ies) for PTCL.
- Adequate bone marrow reserve and organ system functions.
Exclusion Criteria:
- Any unsolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 from previous anti-cancer therapy (except alopecia).
- Active infections, active or latent tuberculosis.
- Patients with severely decreased lung function.
- History of heart failure or QT interval prolongation.
- Central nervous system (CNS) or leptomeningeal lymphoma.
- History of treatment with Janus kinase (JAK) or signal transducer and activator of transcription 3 (STAT3) inhibitor.
- Patient has undergone an allogeneic stem cell transplant. Patient had autologous stem cell transplant within 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD4205 Group A
Group A: Open label AZD4205 at dose A, once daily (Phase 1)
|
AZD4205 will be administered orally as capsules.
AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
|
Experimental: AZD4205 Group B
Group B: Open label AZD4205 at dose B, once daily (Phase 1)
|
AZD4205 will be administered orally as capsules.
AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
|
Experimental: AZD4205 Group C
Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)
|
AZD4205 will be administered orally as capsules.
AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
|
Experimental: AZD4205 Group D
Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)
|
AZD4205 will be administered orally as capsules.
AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Through study completion, an average of 1 year
|
ORR is the percentage of patients with at least one visit response of Complete Response (CR) or Partial Response (PR) based on CT scans per Lugano criteria
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: The first dose until 28 days after last dose
|
To evaluate the safety and tolerability of AZD4205 in patients with PTCL in terms of adverse events (AEs)
|
The first dose until 28 days after last dose
|
Peak Plasma Concentration (Cmax) of AZD4205
Time Frame: 1,8,15, 21 days after first dose
|
1,8,15, 21 days after first dose
|
|
Area under the plasma concentration versus time curve (AUC) of AZD4205
Time Frame: 1,8,15, 21 days after first dose
|
1,8,15, 21 days after first dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Won Seog Kim, PhD, Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DZ2019J0005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Peripheral T Cell Lymphoma
-
AstraZenecaCompletedRelapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins LymphomaItaly, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
-
Sun Yat-sen UniversityRecruitingRelapsed or Refractory Peripheral T-cell LymphomaChina
-
Zhejiang Genfleet Therapeutics Co., Ltd.RecruitingRelapsed or Refractory Peripheral T-cell Lymphoma (PTCL)China
-
Great Novel Therapeutics Biotech & Medicals CorporationRecruitingRelapsed or Refractory Peripheral T-cell LymphomaTaiwan
-
Kura Oncology, Inc.CompletedRelapsed or Refractory Peripheral T-Cell LymphomaUnited States, Spain, Korea, Republic of
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownRelapsed or Refractory Peripheral T-Cell LymphomaChina
-
Samsung Medical CenterCompletedRelapsed or Refractory Peripheral T-cell LymphomaKorea, Republic of
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownRelapsed or Refractory Peripheral T-cell and NK/T-cell LymphomaChina
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
Clinical Trials on AZD4205
-
Dizal PharmaceuticalsCompleted
-
Dizal PharmaceuticalsRecruiting
-
Dizal PharmaceuticalsCompleted
-
Dizal PharmaceuticalsCompletedHealthy VolunteersUnited States
-
Dizal PharmaceuticalsRecruitingHealthy SubjectsUnited States
-
Henan Cancer HospitalRecruiting